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Abstract The S100 proteins MRP8 and MRP14 have been 
shown to be expressed by myeloid cells during inflammatory 
reactions. Since the majority of S100 proteins exhibit their 
biological activity when associated as complex it was investigated 
whether murine MRP8 and MRP14 form heterodimers and 
whether this complex may bind lipids of the cell membrane. This 
is of particular importance since their anchoring into the plasma 
membrane is unclear although upon calcium binding the proteins 
translocate from the cytoplasma to the cytoskeleton and the 
plasma membrane. Using recombinant proteins we could show 
that not the monomers but only the heterodimers specifically bind 
arachidonic acid. This finding opens new perspectives for the role 
of MRP8 and MRP14 in acute and chronic inflammatory 
processes. 
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1. Introduction 
The SI00 proteins MRP8 and MRP 14 are expressed during 
myeloid differentiation and are found in high amounts in 
granulocytes and in monocytes during an early differentiation 
stage, yet are absent from lymphocytes and mature tissue 
macrophages [1]. Phagocytes, expressing MRP8 and 
MRP14, are found in many inflammatory conditions, e.g. 
rheumatoid arthritis, allograft rejection, inflammatory bowl 
and lung diseases [2,3]. Expression of MRP8 and MRP14 
by infiltrating myelo-monocytic cells has been described to 
correlate with disease activities in murine models of experi-
mental inflammation, e.g. irritant and allergic contact derma-
titis, Leishmaniasis or angiogenesis [4,5]. 
Elevated serum levels of MRP8 and MRP 14 were found in 
various inflammatory diseases [2]. Therefore, it was proposed 
to introduce MRP8/14 as a sensitive novel inflammation 
marker [3]. It has been described earlier that human MRP8 
and MRP 14 may form homo- and heteropolymers in a cal-
cium-dependent manner [6]. 
The principal complex is a heterodimer which is found in 
e.g. monocytes. Upon calcium-binding the complex translo-
cates from the cytoplasma to the cytoskeleton and the plasma 
membrane [7,8]. How the complex is anchored in the mem-
brane is not clear since the proteins do not contain a trans-
membrane region [9]. Nevertheless, the proteins can be de-
tected on the surface of the cells. Upon activation of protein 
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kinase C the proteins are also secreted via a novel pathway 
requiring an intact microtubule network [10]. 
So far a number of functions has been proposed for MRP8, 
MRP14 and the heterocomplexes, e.g. antimicrobial, cyto-
static and chemotactic activities. For some of these a molec-
ular mechanism has been elaborated [11,12]. However, no 
ligands or receptors have been found so far for the individual 
proteins or the complexes. 
In view of the lack of a transmembrane domain and the 
failure to identify a protein ligand or anchor in the membrane, 
the question was raised whether MRP8 and/or MRP14 might 
become lipophilic after calcium-binding. Here we could show 
that heterocomplexes of recombinant murine MRP8 and 
MRP 14 specifically bind arachidonic acid in a strictly calci-
um-dependent manner, whereas the individual proteins are 
inactive. This finding suggests an intimate link of MRP8/14 
to arachidonic acid and its metabolites which are principally 
involved in the initiation, propagation and termination of in-
flammatory processes. 
2. Material and methods 
2.1. cDNA cloning 
Mouse spleen RNA was extracted using the guanidine-isothiocya-
nate phenol extraction and first strand cDNA was synthesized accord-
ing to common molecular biology techniques [13]. Using primers 
MRP8-1 (5'-ATGCCGTCTGAACTGGAG), MRP8-2 (5'-TACTC-
CTTCTGGCTGTCT), MRP14-1 (5'-ATGGCCAACAAAGCACCT) 
and MRP14-2(TTACTTCCCACAGCCTTT) double-stranded cDNA 
of murine MRP8 and MRP 14 was synthesized using polymerase chain 
reaction (95°C 1 min; 50°C 1 min, 72°C 1 min, 35 cycles) and sub-
sequently cloned into pSP72 (Promega, Heidelberg, Germany). 
2.2. Expression and purification of recombinant proteins 
After subcloning into pQE32 (Qiagen, Hidden, Germany) MRP8 
and MRP 14 were expressed and purified: bacterial cultures were cen-
trifuged (3000 Xg, 20 min) and subsequently resuspended in buffer 1 
(8 M urea, 50 mM NaH2P04, 15 mM Imidazol, 10 mM Tris-HCl, 100 
mM NaCl; pH 8.0 (all chemicals are obtained from Boehringer In-
gelheim Bioproducts, Heidelberg, Germany, unless otherwise stated). 
After sonification the cell lysate was centrifuged at 20000Xg for 30 
min. The supernatant was purified using immobilized metal affinity 
chromatography (Clontech, Palo Alto, CA); elution was performed 
using buffer 1 at pH 6.0 supplemented with 100 mM Imidazol. The 
proteins were dialysed in 20 mM NHtAc, pH 5.0, and lyophilized. 
Subsequent analysis by polyacrylamide gel electrophoresis (PAGE) 
revealed that the recombinant murine MRPs were 95-98% pure 
(data not shown). 
2.3. Complex formation of MRP8 and MRP14 
To investigate the possibility of these proteins to form complexes 50 
μg of each protein alone or 25 μg of each protein in combination were 
resuspended in 50 mM CaCl2, 5% ß-mercaptoethanol, boiled for 5 min 
and dialysed for 36 h against 50 mM CaCl2 in 15 mM HEPES, 
pH 8.0, exchanging the buffer twice. After dialysis the samples were 
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freeze dried and subsequently resuspended in SDS sample buffer (150 
mM Tris-HCl, pH 8.5, 0.1% SDS, 10% glycerol, 0,1% bromphenol 
blue), boiled for 2 min, and analysed by 15% SDS-PAGE. Gels were 
stained using Coomassie standard procedure. 
2.4. Binding to fatty acids 
In a first set of experiments recombinant mouse MRP8 and MRP 14 
proteins were treated according to the procedure described above, 
with the exception that the dialysis buffer was TBS (50 mM Tris-
HCl, 150 mM NaCl) containing 50 mM CaCl2. When dialysis was 
completed, the samples were adjusted to a concentration of 100 μg/ml 
and equally divided into two vials. One vial was assayed using the 
procedure described below and the other sample was supplemented 
with EDTA at a final concentration of 25 mM. An aliquot of 100 μΐ 
containing 10 μg of protein of each sample was incubated with 20 μΐ 
of 4.8 μΜ 14C-labelled arachidonic or oleic acid (Amersham, 
Braunschweig, Germany) for 30 min at 37°C. Unbound fatty acids 
were removed from fatty acids associated to MRPs using micro G-25 
spin columns (Pharmacia, Freiburg, Germany) according to the man-
ufactors' instruction. To verify Ca2+-dependent binding of the arach-
idonic acid to the MRPs, the proteins were dialysed against TBS in 
the absence of Ca2+. To establish different Ca2+ concentrations, dif-
ferent amounts of CaCl2 were added to give a final concentration of 
25, 50, 100 and 1000 μΜ. After incubation for 30 min at 37°C radio-
active labelled arachidonic acid was added and the experiment was 
further continued as described above. Coelution of the recombinant 
mouse MRP8/14 and arachidonic acid was performed following in-
cubation of the protein with labelled arachidonic acid in TBS in the 
presence of 100 μΜ Ca2+ for 30 min at 37°C. Subsequently, the 
protein-bound fatty acid was removed from unbound fatty acid by 
gel filtration (PD-10 columns, Pharmacia). Aliquots of 500 μΐ were 
collected and analysed for protein and fatty acid content by UV-VIS 
spectroscopy and liquid scintillation counting, respectively. 
3. Results and discussion 
A SDS-PAGE using non-reducing conditions loaded with 
recombinant mouse MRP8 or recombinant mouse MRP 14 
reveals two major bands in each lane with a molecular mass 
of 11 kDa and 22 kDa for MRP8 and 14 kDa and 28 kDa for 
MRP14, respectively (Fig. 1, lanes 2 and 3). After incubation 
of both MRPs in Ca2+-rich buffer, an additional band occurs 
(Fig. 1, lane 1). To verify the assumption that the high mo-
lecular mass proteins indeed are homo- and heterodimers, the 
bands were eluted from the gel, boiled for 5 min with 1% ß-
mercaptoethanol to reduce the samples and applied to a re-
ducing SDS-PAGE. As expected the homodimers of MRP8 
and MRP 14 contain only elements of 11 kDa (MRP8) or 14 
kDa (MRP14), respectively (Fig. 1, lane A and B). The sup-
posed heterodimer of mouse MRP8 and MRP 14 consists of a 
11 kDa (MRP8) and a 14 kDa (MRP14) protein (Fig. 1, lane 
C). Therefore, recombinant mouse MRP8 and MRP14 form 
homo- and heterodimers in a similar manner as shown for 
natural human MRPs [6]. Additionally the complexes have 
been shown to be formed in the presence of calcium. 
The recombinant mouse proteins described above were used 
in different combinations to analyze the binding of MRPs to 
fatty acids. Only the MRP8/MRP14 complex significantly and 
specifically binds arachidonic acid. Up to 48% of radioactively 
labelled arachidonic acids added in substochimetrial amounts 
remained bound to the heterodimer after separation. In con-
trast only 9% of the arachidonic acid remained bound to the 
monomers and homodimers (Fig. 2). It is obvious that the 
binding of arachidonic acid critically dependents on the for-
mation of the protein complex, which is supposed to be 
formed in vivo after cell activation [6]. 
Furthermore, it could be demonstrated that the binding of 
arachidonic acid is also dependent on the presence of Ca2+ 
reflecting physiological concentrations (Fig. 3A). Additional-
ly, the binding of the MRP8/14 complex to arachidonic acid 
could be prevented by addition of EDTA to the reaction (Fig. 
2), although the presence of EDTA does not destabilize the 
heterodimer once it has formed (data not shown). 
The affinity of MRP complex to arachidonic acid is further 
demonstrated by a coelution experiment. Bound arachidonic 
acid coelutes with the heterodimer, whereas free arachidonic 
acid forms a second, clearly distinguishable peek (Fig. 3B). 
The distinct interaction of the MRP8/MRP14 heterodimer 
with arachidonic acid was in contrast to the faint binding of 
the complex to oleic acid (13% vs. 48% of the total fatty acid 
bound to the MRP8/MRP14 complex, Fig. 2). This demon-
strates the specific affinity of the MRP heterodimer to arach-
idonic acid unlike other proteins known to unspecifically as-
sociated with a diversity of lipophilic compounds. This 
conclusion can be drawn as arachidonic acid is a 20 C-atom 
polyunsaturated molecule (20:4Δ5,811'14), whereas oleic acid is 
a mono-unsaturated 18 C-atom fatty acid (18:1Δ9). Whether 
the heterodimer exclusively binds arachidonic acid or related 
derivatives (e.g. prostaglandines) as well, needs to be further 
investigated. The determination of the physical properties of 
the binding could add valuable information on whether 
MRP8/14 act primarily as a transport carrier or has a func-
tional role itself. 
The interactions of S-100 proteins with fatty acids have not 
Fig. 1. Recombinant mouse MRP8 and MRP14 on SDS-PAGE (15%) under non-reducing conditions (left): lane 1, MRP8 and MRP14; lane 
2, MRP14; lane 3, MRP8. The bands A-C were extracted from the left gel and reloaded on reducing PAGE (right): lanes A-C correspond 
with the homodimers of MRP8; homodimers of MRP14 and heterodimer of MRP8 and MRP14, respectively. 
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Fig. 2. Binding of recombinant mouse MRP8 and MRP14 to arachidonic and oleic acids. The heterodimer MRP8/MRP14 binds arachidonic 
acid significantly, whereas the interaction of monomers and homodimers is negligible. Binding of arachidonic acid to the MRP8/MRP14 com-
plex was absent in the presence of EDTA. Control experiments using oleic acid resulted only in a minor binding. 
been studied extensively so far. One report suggests the inter-
action of S-100 proteins with fatty acids in adipocytes [14]. 
Follow-up studies of this observation have not been pub-
lished. Recently, another group searching for arachidonic 
acid binding proteins in human keratinocytes identified 
MPR8/MRP14 as a potential candidate [15]. 
The biological significance of our findings remains unclear. 
It is known that agents that raise calcium levels in cells, e.g. 
monocytes, induce phospholipase A2 which leads to the cleav-
age of arachidonic acid from the glycolipid in the membrane. 
Arachidonic acid is rapidly metabolized via the lipoxygenase 
and cycloxygenäse controlled pathway [16]. Parallel to these 
events calcium is bound by MRP8/MRP14 complexes which 
translocate to the cytoskeleton and the plasma membrane. If 
phosphokinase C is activated, i.e. by arachinoidate [17] this 
also leads to the secretion via a novel microtubule-dependent 
pathway of MRP8/14 [10]. An important question is whether 
MRP8/14 is released as a free complex or with arachidonic 
acid bound to it. Another question is whether arachidonic 
acid is the anchor molecule for the protein complex in the 
membrane. If S-100 proteins in general are bound to fatty 
acids or subsets of fatty acids, this aggregation would increase 
the hydrophobicity. Subsequent translocation to the cell mem-
brane could be the initial event which may finally lead to 
secretion of the S-100 proteins. 
The interaction with free arachidonic acid allows to con-
ceive several possibilities. Binding of arachidonic acid could 
be a way to limit the pro-inflammatory action of arachidonic 
acid. These actions are very specific, since arachidonic acid 
but not eicosapentaenoic acid pretreatment of granulocytes 
results in a release of elastase [18], which decreases endothelial 
integrity. Furthermore, the export to the extracellular space 
and the high amounts of MRP8/14 complexes in body fluids 
of patients with acute and chronic inflammatory diseases [2,3] 
raises the question whether MRP8/14 is merely a transport 
protein or the arachidonic acid protein complex has functions 
Fig. 3. Binding of recombinant mouse MRP8/MRP14 complex to 
arachidonic acid is Ca2+ dependent (A) even at low concentrations 
and is saturated at 50 μΜ Ca2+. Coelution of arachidonic acid to-
gether with the MRP8/MRP14 protein complex as demonstrated us-
ing 100 mM Ca2+ (B) further supports the specificity of this interac-
tion. 
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of its own. A number of reports on biological functions would 
have to be revisited in view of the fact that the protein com-
plex isolated from sera of patients with inflammatory diseases 
bear arachidonic acid or not. 
In summary, the specific binding of M R P 8 / M R P 1 4 complex 
to arachidonic acid opens a new horizon for the biology of 
these proteins in combination with fatty acids. It links a well-
established system of inflammatory mediators with a group of 
proteins whose involvement in the inflammatory process has 
been well documented. 
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